| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions ('transcription factors') to ask one cell type to become another. Our lead program is focused on unlocking innate repair mechanisms to restore sight, initially for the 1.5 million individuals worldwide suffering from Retinitis Pigmentosa. |
| Category: | Health & biotech |
| URL: | www.mirugen.com |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2022 |
| Address: | Melbourne Australia |
| State: | Victoria |
| Overseas Operations: | |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/mirugen |
| Founders: |
No items found
|
| Awards won: | |
